Pathos AI struck a deal for rights to a bispecific antibody drug conjugate from Alphamab that could become first in a new class of cancer drugs. Separately, the startup began a partnership with AstraZeneca on a protein degrader from the pharma company’s cancer drug pipeline.
The post Pathos Picks Up Two Cancer Drugs Poised for Clinical Development With AI Agents appeared first on MedCity News.
